The estimated Net Worth of Alan F Holmer is at least $580 Thousand dollars as of 14 June 2024. Mr. Holmer owns over 1,667 units of Corbus Pharmaceuticals Inc stock worth over $307,247 and over the last 9 years he sold CRBP stock worth over $0. In addition, he makes $273,122 as Independent Chairman of the Board at Corbus Pharmaceuticals Inc.
Sign up
Mr. Holmer CRBP stock SEC Form 4 insiders trading
Alan has made over 6 trades of the Corbus Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,667 units of CRBP stock worth $50,010 on 14 June 2024.
The largest trade he's ever made was exercising 10,000 units of Corbus Pharmaceuticals Inc stock on 25 August 2015 worth over $10,000. On average, Alan trades about 822 units every 179 days since 2015. As of 14 June 2024 he still owns at least 5,829 units of Corbus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Holmer stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alan Holmer biography
Alan F. Holmer J.D. serves as Independent Chairman of the Board of the Company. From 1996 to 2005 he served as President and Chief Executive Officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), an organization that represents the worldwide interests of leading pharmaceutical and biotechnology companies, based in Washington, D.C. From 2005 to 2007 and again from February 2009 until its acquisition by Merck in May 2011, Mr. Holmer served as a Director of Inspire Pharmaceuticals, Inc., and at various times as member of its Corporate Governance Committee, Audit Committee, and Drug Development Committee. In addition to his pharmaceutical industry experience, Mr. Holmer has significant expertise in handling legal, international trade and governmental issues, having held various positions within the office of the U.S. Trade Representative, the Commerce Department and the White House, including serving as Deputy U.S. Trade Representative with rank of Ambassador. Mr. Holmer served as Special Envoy for China and the Strategic Economic Dialogue, a position to which he was appointed by Secretary of the Treasury, Henry M. Paulson, Jr. from 2007 to 2009. Mr. Holmer also served as a partner at the international law firm, Sidley & Austin (now Sidley Austin LLP), and as an associate at Steptoe & Johnson LLP. From 2012 to 2016, Mr. Holmer served as Special Counsel in the Washington, D.C. office of Smith, Currie & Hancock LLP. Mr. Holmer has been involved in many community service organizations, including as the former Chairman of the Board of the Metropolitan Washington, D.C., Chapter of the Cystic Fibrosis Foundation (2009 to 2018). He also served as Co-Chairman of the President’s Advisory Council on HIV/AIDS. Mr. Holmer received an A.B. degree from Princeton University and a J.D. from Georgetown University Law Center. Mr. Holmer was selected as a director because of his background in the pharmaceutical and biotechnology industry and his experience in governance matters.
What is the salary of Alan Holmer?
As the Independent Chairman of the Board of Corbus Pharmaceuticals Inc, the total compensation of Alan Holmer at Corbus Pharmaceuticals Inc is $273,122. There are 6 executives at Corbus Pharmaceuticals Inc getting paid more, with Yuval Cohen having the highest compensation of $4,001,510.
How old is Alan Holmer?
Alan Holmer is 70, he's been the Independent Chairman of the Board of Corbus Pharmaceuticals Inc since 2014. There are 1 older and 10 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.
What's Alan Holmer's mailing address?
Alan's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.
Insiders trading at Corbus Pharmaceuticals Inc
Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor..., and Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.
What does Corbus Pharmaceuticals Inc do?
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
What does Corbus Pharmaceuticals Inc's logo look like?
Complete history of Mr. Holmer stock trades at Corbus Pharmaceuticals Inc
Corbus Pharmaceuticals Inc executives and stock owners
Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Yuval Cohen,
Chief Executive Officer, Director -
Barbara White,
Chief Medical Officer -
Sean Moran,
Chief Financial Officer -
Dr. Yuval Cohen,
CEO & Director -
Rachelle Jacques,
Independent Director -
Sean F. Moran CPA, M.B.A., CPA, MBA,
Chief Financial Officer -
Alan Holmer,
Independent Chairman of the Board -
Avery Catlin,
Independent Director -
John Jenkins,
Independent Director -
Ted Jenkins,
Senior Director, Investor Relations and Communications -
Peter Salzmann,
Independent Director -
Craig Millian,
Chief Commercial Officer -
Scott Constantine,
Sr. Director & Head of Clinical Operations -
Christina Bertsch,
Head of HR -
Lindsey Smith,
Head of Corp. Communications & Patient Advocacy -
Dr. Rachael Brake Ph.D.,
Chief Scientific Officer -
Craig Stuart Millian M.B.A.,
Chief Operating Officer. -
David P Hochman,
Director -
Mark Tepper,
President and CSO -
Renu Gupta,
Director -
George Golumbeski,
Director -
Asset Management, Lp Cormor...,
-
Anne Altmeyer,
-
Yong Ben,
-
Paris Panayiotopoulos,
Director -
Asset Management, Lp Chen B...,
-
Dominic Smethurst,
Chief Medical Officer -
Sumner Burstein,
10% owner -
Robert Paul Discordia,
Chief Operating Officer -
Rachael Louise Brake,
Chief Scientific Officer -
Winston Kung,